ABSTRACT
BACKGROUND: Sotrovimab is an anti-spike neutralization monoclonal antibody (mAB) developed to reduce the risk of Coronavirus Disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancies (HM) and the predictive factors of hospitalization. METHODS: We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19-related hospitalization(s) compared to those who did not. RESULTS: Among the 156 study patients, seventeen (17, 11%) were hospitalized of which four were readmitted for COVID-19-related complications; three deaths were attributed to COVID-19. Results from multivariable logistic regression show significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted OR = 5.59, 95% CI (1.73 - 18.12), p = 0.004) and with relapse/refractory disease (adjusted OR = 5.69, 95% CI (1.69 - 19.16), p = 0.005). Additionally, whole-genome sequencing of SARS-CoV-2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab. CONCLUSIONS: While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in HM patients when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.
ABSTRACT
Introduction:There is conflicting data on the association of blood type with COVID-19 infection. Recent studies have shown an association of blood type in acquisition of COVID-19 infection (Zhao et al., medRxiv 2020), but no association in terms of disease mortality (Latz, Ann Hematol 2020). Prior studies are limited due to lack of diversity. One of the largest studies conducted in China found blood type A conferred highest risk of acquiring COVID-19 infection (Zhao et al., medRxiv 2020). Similar results were found in which the odds of COVID-19 positive infection compared to negative test results were increased in blood group A and decreased in blood group O (Zietz et al., medRxiv 2020). There was no significant association between blood group and intubation or death. Neither of these studies addressed the association of blood groups with thromboembolism. This study aimed to evaluate the impact of blood types on outcomes of COVID-19 infection in a multiracial population.Methods:This is a retrospective electronic chart review of all patients admitted to New York-Presbyterian Brooklyn Methodist Hospital in Brooklyn, NY. All patients admitted from March 2020 to April 2020 who tested positive for SARS-CoV-2 nasopharyngeal swab were analyzed. Baseline patient characteristics and outcomes were entered manually by medical professionals via chart review using the electronic medical record (EMR). Baseline characteristics include blood group type, rhesus antigen status, age, gender, race, comorbid conditions, median initial and peak D-dimer. The primary endpoint was inpatient mortality. The secondary endpoints included thromboembolism (pulmonary embolism, deep venous thrombosis, arterial thrombosis), myocardial infarction, bleeding event, length of stay, intensive care unit admission, and intubation. Chi-square test for categorical variables was used to calculate statistical significance defined as p value ≤ .05 when comparing ABO blood group and rhesus antigen with mortality and development of thromboembolism.Results:Our study consisted of 249 patients that were COVID-19 positive with a documented blood group. Our population consisted of 51% of patients that identified as black, 35.7% that identified as white, and 17.7% that identified as Hispanic. Blood type B had the highest rate of patients that identified as black at 58.1% and blood type O had the highest rate that identified as Hispanic at 23.6%. When comparing blood groups A, AB, B and O to the rate of mortality the result was 46%, 44.4%, 41.9% and 50.9% respectively which was found to be not statistically significant (p=0.759). Rh positive patients had a 47.2% mortality rate while Rh negative patients had a 46.9% mortality rate however this was also found to be not statistically significant (p=0.954). Next, we compared development of thromboembolism during hospital stay in the A, AB, B, and O blood type groups and the rate was 8%, 11.1%, 9.3%, and 10.9% respectively with the results not being statistically significant when accounted for blood type (p=0.991). Rate of development of thromboembolism in Rh positive and negative patients was 9.3% and 9.4% respectively which was found to not be statistically significant as well (p=0.998). When looking at comorbidities, 70.2% of our patient population had hypertension and the second prevalent comorbidity was diabetes at 38.2% (Table 1).Discussion:In a diverse population, no association between ABO blood group, Rh status, and mortality was found which is similar to the conclusion found in prior studies done by Zhao et al. and Latz et al. in which the majority of the population was either Caucasian or Asian. Additionally, there is no association found between ABO blood group, Rh status and development of thromboembolism. Our patient population consisted mostly of minority groups.Prior studies have shown that blood type A has the highest risk of positive SARS-CoV-2 test whereas type O has the lowest risk of positive SARS-CoV-2 test. Our study further supplements this discovery by the conclusion that while blood type A confer ed highest risk of acquiring COVID-19 infection, blood type had no significant association with mortality. Investigation on a larger scale is necessary to address the susceptibility of ABO blood group and COVID-19 infection severity in a multiracial population to address racial disparities.
ABSTRACT
Background: At the beginning of the COVID-19 pandemic, New York City quickly became the epicenter with hospitals at full capacity needing to care for patients. At New York Presbyterian Brooklyn Methodist Hospital, we needed to develop an innovative system of how to safely discharge the massive influx of patients. Inundation of patient care with limited manpower and resources forced us to align with a third-party vendor, around-the-clock alert, to make remote patient monitoring (RPM) possible. Each patient was prescribed a pulse oximeter and nurses were assigned to monitor vital signs, speak to patients, and escalate to physicians if required. Results: We enrolled 50 patients, of whom 13 were escalated resulting in 3 emergency room visits and 1 readmission. We had a high compliance rate with high patient satisfaction in postsurveys. Discussion: Our program was unique in that it utilized telemedicine for regular patient follow-up, along with RPM through a third-party vendor. Patients were able to be safely discharged home with close follow-up through regularly obtained vitals with access to a 24/7 hotline for any emergencies, possibly preventing readmissions. Limitations include a small sample size population. Conclusions: Our experience shows that in a short period despite lack of resources, telehealth and RPM's concurrent use with a third-party vendor could be successfully utilized for safe discharges with high patient satisfaction.